BioData, producer of Labguru, the web-based research and lab management system, has announced that the Innovative Medicines unit of global pharmaceutical business, AstraZeneca, has adopted the Labguru platform for the global management of biological reagents used in pre-clinical research.
Scientists will use the Labguru platform across multiple AstraZeneca sites in North America and Europe, replacing and consolidating several legacy systems spanning several scientific disciplines. Its modular web-based system offers an easy means of tracking projects, protocols, biological collections and materials, as well as streamlining collaboration between members of the lab and between institutions.
Lorenz Mayr, VP of Reagents and Assay Development at AstraZeneca explained: “We conducted a comprehensive evaluation and found Labguru to be the most suitable solution for the management of our global preclinical biological reagents. BioData’s experience with supporting academic groups, together with the cloud-based Labguru installation, will allow AstraZeneca scientists greater opportunities to share our biological research reagents with future external partners, to support new drug discovery projects for which there is currently an unmet medical need.”
Louis Culot, Chief Executive Officer of BioData said: “AstraZeneca selected Labguru after a rigorous assessment of their needs and available solutions. Our approach comprising an integrated scientific research platform that currently enables multi-site academic collaboration, is resulting in measurable improvements in laboratory management, scientific reproducibility, and transparency. We look forward to supporting AstraZeneca's vision of delivering life-changing medicines to patients."
A Digital Science portfolio company, BioData’s services benefit individual researchers at the bench, and also enhance collaboration and knowledge management across research teams and institutions. Labguru’s order management, equipment sharing, and storage mapping features reduce costs and streamline administrative tasks.
With offices in Boston, Tel Aviv, and London, BioData creates digital tools for increasing the productivity of academic and industry laboratories. Its flagship product, Labguru, is currently used by thousands of researchers in hundreds of labs worldwide. Founded in 2007, BioData is a portfolio company of Digital Science, a division of Macmillan Science & Education and sister company to Nature Publishing Group. www.labguru.com.
Digital Science is a global technology company serving the needs of scientific research. Its mission is to fuel scientific discovery with software that makes research simpler. Whether at the bench or in a research setting, their range of products help at every stage of the research cycle and change the way science is done. Its portfolio brands include Altmetric, Labguru, Figshare, Overleaf, ReadCube, ÜberResearch, BioRAFT and Symplectic. Digital Science is a business division of Macmillan Science and Education. www.digital-science.com
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information visit www.astrazeneca.com
